↓ Skip to main content
What is this page? Embed badge

A phase II study of the potent PARP inhibitor, Rucaparib (PF-01367338, AG014699), with temozolomide in patients with metastatic melanoma demonstrating evidence of chemopotentiation

Overview of attention for article published in Cancer Chemotherapy and Pharmacology, February 2013
Altmetric Badge

About this Attention Score

  • Average Attention Score compared to outputs of the same age
  • Average Attention Score compared to outputs of the same age and source

Mentioned by

patent
1 patent

Citations

dimensions_citation
157 Dimensions

Readers on

mendeley
85 Mendeley
Summary Patents Dimensions citations
So far, Altmetric has seen 1 patent that references this research output.

This page is provided by Altmetric.